

Figure 1: ONWARD study design



*prior to an early protocol amendment, the ONWARD study included randomisation to treatment with cladribine tablets 5.25 mg/kg (cumulative dose over 2 years) + IFN-β

Figure 2: Qualifying relapse rate (annualized, adjusted) in patients with SPMS treated with cladribine tablets 3.5 mg/kg + IFN-β or placebo + IFN-β in ONWARD



CI, confidence interval; IFN-β, interferon-β. SPMS, secondary progressive multiple sclerosis





Figure 3. Qualifying relapse rate (annualized, adjusted) in patients with RRMS treated with cladribine tablets 3.5 mg/kg + IFN-β or placebo + IFN-β in ONWARD

CI, confidence interval; IFN-β, interferon-β. RRMS, relapsing-remitting multiple sclerosis

Figure 4 Study Design Schematic



9-HPT=9-Hole Peg Test, EDSS= Expanded Disability Status Scale, MRI=magnetic resonance imaging; T25FW=Timed 25-Foot Walk, TP=treatment period.